Cingulate Inc. (NASDAQ:CING) shares were down during Friday’s premarket session but recovered later. The company’s recent financial report highlighted both operational advancements and ongoing challenges.
The stock’s volatile move comes as broader markets experienced mixed performance, with the S&P 500 futures down 0.6% and the Healthcare sector remaining flat.
Cingulate reported a net loss of $6.3 million for the fourth quarter of 2025, slightly up from a loss of $6.2 million in the same period the previous year.
Additionally, the company announced the granting of a European patent for its ADHD treatment, CTx-1301, which is expected to bolster its intellectual property portfolio and support future commercialization efforts.
The company also secured a $12 million private investment to …
This post was originally published here
